
Toxicity.

late-onset aGvHD
ADVERSE EVENTS, ADVERSE EVENT
Treatment-related adverse events (AEs) are summarized in Table Adverse Events During Antibody Treatment (N = 68)Occurrence of late-onset aGvHD during DB treatment was low (n = 5; 7.4%). Two patients developed grade 2 and 3 aGvHD of the gut. Three patients (4.4%) developed grade 1/2 skin GvHD, without the need for systemic therapy. No grade 4 GvHD was reported. No additional AEs were observed in the presence of low-dose scIL2.